Experiences with
Tyrosine745 public posts
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial
A new BTK inhibitor enters the fray in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma.
ONO-4059 is currently being developed in a Phase I clinical trial for the treatment of B-cell malignancies.
A Phase I Study in CLL patients of ONO-4059
UK: Cardiff (Wales), Leicester
FDA application made for Ibrutinib in refractory/relapsed CLL/SLL ONLY
Ibrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor being jointly developed by Janssen and Pharmacyclics, Inc. for the treatment of B-cell malignancies.
Read more here:
http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=776062
Want to take advantage of all our features? Just log in!
or
How does thyroid hormone find its way into the brain?
tyrosine
Others:
. thyroxine
. 5-hydroxytryptophan
. L-DOPA
I warn you that some of the paper could be upsetting in its description of the effect on some people of transporter mutations.
[i]How does thyroid hormone (TH) find its way into the brain?
A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia?
'The New England Journal of Medicine (NEJM) has published data online about the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib as a monotherapy in patients with chronic lymphocytic leukemia (CLL).
The cost of new therapies...like TKIs
chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts
'As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine
Evolutionary roots of iodine and thyroid hormones in cell–cell signaling
From an initial role as membrane antioxidant and biochemical catalyst, spontaneous coupling of iodine with tyrosine appears to have created a versatile, highly reactive and mobile molecule, which over time became integrated into the machinery of energy production, gene function, and DNA replication in
Syk inhibitor... new target kinase... pre-clinical characteristics of P505-15
B-cell receptor (BCR) associated kinases including spleen tyrosine kinase (SYK) contribute to the pathogenesis of B-cell malignancies.